{'fraction_non_alphanumeric': 0.02796420581655481, 'fraction_numerical': 0.0044742729306487695, 'mean_word_length': 6.217741935483871, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Cross-infection causes the most concern and discussion amongst cystic fibrosis (CF) health professionals, patients and carers. It causes concern because microbiological status can influence the quality of life and survival of a CF patient.1–3 The list of bacterial pathogens documented as responsible for cross-infection outbreaks is lengthening and currently includes Burkholderia cepacia complex, methicillinresistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Pandoraea spp.4–7 We consider current cross-infection problems in CF and discuss the clinical problems associated with cross-infection, highlighting the major pathogens involved and the consequences of cross-infection for individual patients, specialist centres and the CF community.